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Abstract
Introduction: Retail pharmaceutical products are commonly used to treat fever and malaria in sub-Saharan African
countries. Small scale studies have suggested that poor quality antimalarials are widespread throughout the region, but
nationwide data are not available that could lead to generalizable conclusions about the extent to which poor quality drugs
are available in African communities. This study aimed to assess the quality of antimalarials available from retail outlets
across mainland Tanzania.
Methods and Findings: We systematically purchased samples of oral antimalarial tablets from retail outlets across 21
districts in mainland Tanzania in 2005. A total of 1080 antimalarial formulations were collected including 679 antifol
antimalarial samples (394 sulfadoxine/pyrimethamine and 285 sulfamethoxypyrazine/pyrimethamine), 260 amodiaquine
samples, 63 quinine samples, and 51 artemisinin derivative samples. A systematic subsample of 304 products was assessed
for quality by laboratory based analysis to determine the amount of the active ingredient and dissolution profile by
following the published United States Pharmacopoeia (USP) monogram for the particular tablet being tested. Products for
which a published analytical monogram did not exist were assessed on amount of active ingredient alone. Overall 38 or
12.2% of the samples were found to be of poor quality. Of the antifolate antimalarial drugs tested 13.4% were found to be
of poor quality by dissolution and content analysis using high-performance liquid chromatography (HPLC). Nearly one
quarter (23.8%) of quinine tablets did not comply within the tolerance limits of the dissolution and quantification analysis.
Quality of amodiaquine drugs was relatively better but still unacceptable as 7.5% did not comply within the tolerance limits
of the dissolution analysis. Formulations of the artemisinin derivatives all contained the stated amount of active ingredient
when analysed using HPLC alone.
Conclusions: Substandard antimalarial formulations were widely available in Tanzania at the time of this study. No products
were detected that did not contain any amount of the stated active ingredient. Quinine and sulfadoxine/pyrimethamine
products were the most widely available and also the most likely to be of poor quality. Substandard products were
identified in all parts of the country and were labeled as made by both domestic and international manufacturers. With the
expansion of the retail pharmaceutical sector as a delivery channel for antimalarial formulations the need for regular
nationwide monitoring of their quality will become increasingly important.
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Introduction
Plasmodium falciparum malaria is estimated to be the direct cause
of 213.5 million clinical episodes per year in Africa and 1.14
million deaths [1]. It is therefore of vital importance that
antimalarial drugs administered are genuine and of high quality.
Poor quality drugs can be divided into 2 categories: counterfeit
and substandard. Counterfeit drugs are deliberately and fraudu-
lently mislabelled with respect to identity, source, or both.
Counterfeiting can apply to both branded and generic products
and could include products with the correct ingredients or with the
wrong ingredients, without active ingredient, with insufficient
active ingredient, or with fake packaging [2]. Substandard drugs
are genuine drug products that upon laboratory testing do not
meet the quality specifications claimed by their manufacturer. This
may reflect substandard manufacturing technology, or inappro-
priate storage and transportation. Many developing countries do
not have the technical, financial, or human resources required to
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Organisation has estimated that about 25% of the medicines
consumed in developing countries are counterfeit. In some
countries the figure is thought to be as high as 50% [3].
Suspect drugs not only contribute directly to malaria deaths, but
may also lead to an increase in the incidence of drug resistance [4],
which is among the most important threats to health in tropical
countries [5]. Furthermore the presence of counterfeit/substan-
dard drugs in the market undermines public confidence in
pharmaceutical products and may result in a reduced uptake of
potentially lifesaving medicines [6].
The retail sector represents an important source of antimalarials
in Africa; a recent review found that the proportion of caregivers
seeking treatment from shops during recent childhood illness
ranged from 15% to 83%, with a median across studies of
approximately 50% [7]. Little is known about the source and
quality of products stocked, although several small-scale studies
have documented the presence of poor quality antimalarial drugs
in the African retail market [4]. Moreover, with the increase in
artemisinin availability and demand, the prevalence of counterfeit
products of this new class of drug may spread quickly, following
the pattern observed in SE Asia [8].
Existing African studies of antimalarial quality are restricted to
relatively small numbers of samples, collected in limited geo-
graphical areas, generally using convenience sampling. In this
study we undertook the first nationwide study of the quality of
antimalarial drugs available in the retail sector in rural Africa. We
collected samples of oral antimalarial tablets from retail outlets
across mainland Tanzania and assessed them using standard
methods for evaluating dissolution and amount of active
ingredient. Data collection focused on rural areas, reflecting the
geographical pattern of the malaria disease burden in Tanzania.
The results document the scale of the problem in Tanzania and
will serve as a baseline for the evaluation of trends over time, and
the effectiveness of quality improvement strategies. In addition, we
investigated risk factors for poor quality (e.g. type of shop,
geographical location, generic type, country of manufacture) to
help target interventions to improve antimalarial quality.
Methods
Background to the Tanzanian retail market for
antimalarials
The Tanzanian retail sector plays an important role in
antimalarial provision. For example, in 3 rural Tanzanian districts
the majority of provider visits for fever/malaria were to retail
outlets, which supplied 38% of antimalarial sales volumes [9]. At
the time of the collection of these antimalarial samples the first line
antimalarial was sulphadoxine-pyrimethamine (SP) or sulpha-
methoxypyrazine-pyrimethamine (SMP). Amodiaquine was the
second line, and quinine the third line but first choice in treatment
of severe malaria (SP was replaced as first line by artemether-
lumefantrine in late 2006, after this sample collection was
complete). Treatment for uncomplicated malaria was provided
by hospitals, health centres and dispensaries. However, antima-
larials were also widely available from the retail sector, comprising
Part I pharmacies, Part II drug stores and general shops. Part I
pharmacies were required to be run by a registered pharmacist,
and can legally sell any Tanzanian-registered drug, including
prescription only and over the counter medicines [10]. These
outlets were rare in rural areas. Part II drug stores can be staffed
by anyone with a minimum of 4 years medical training (e.g. nurse,
pharmacy assistant). They were permitted to stock over the
counter products only, such as painkillers and oral formulations of
amodiaquine, although it was known that they frequently stocked
prescription only products, such as other antimalarials, antibiotics
and injectable medications [10]. In 2003 there were 5666 registered
Part II drug stores in Tanzania, although in reality this figure is
probably much higher [11]. General shops ranged from large shops
to small roadside stalls, typically stocking a mixture of food products
and household goods, and a few medicines, such as common
painkillers and the occasional antimalarial. General retailers were
not permitted to sell drugs officially, but in practice, the government
allowed the sale of over-the-counter products. These shops were
extremely numerous and very accessible, even to rural populations,
although only a minority stocked antimalarials [12].
Sample collection
Antimalarial drug samples were collected from 21 of the 121
districts in mainland Tanzania between 16th May and 24th
September 2005 (Figure 1). Sample collection was completed as
part of a nationwide survey to assess the impact of the Tanzania
National Voucher Scheme for insecticide-treated nets and retreat-
ment products [13]. Districts were selected randomly, stratified by
the date of implementation of the insecticide-treated net voucher
program (early, middle and late implementers). Of the 21 districts,
16 experienced endemic malaria transmission throughout the entire
district,while5containedepidemicproneareas.Ineachdistrict30%
of wards (=n) were surveyed. Each ward was considered to be a
‘‘trading centre’’. Wards were ordered by the number of businesses
registered with the District level Business Office, and divided into
major trading centres (MTC) (the 50% of wards with the highest
number of businesses) and non-major trading centres (NMTC), the
remaining wards. Categorisations were confirmed through discus-
sion with key informants. Half of the sample was made up of the n/2
largest MTC, to reflect the key commercial areas. An additional n/2
centres were randomly selected from the NMTC to represent
smaller commercial areas.
Figure 1. Districts where antimalarial drugs were collection in
mainland Tanzania, 2005.
doi:10.1371/journal.pone.0003403.g001
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shops, kiosks, hawkers, pharmacies and supermarkets) were visited
and antimalarial tablet samples were collected at each shop where
they were stocked on the day of the visit. In total 2474 shops were
visited of which 8 were designated as Part I pharmacies, 266 as
Part II drugs stores, 2178 as general retailers, and 22 as ‘other’ or
‘unknown’. No drugs were available for purchase in any of the 22
shops designated as ‘other’ or ‘unknown’.
A complete course or adult dose of each of the antimalarial
tablet products stocked was purchased for collection from each
shop visited. Syrups and injectables were not collected, as they
were responsible for a relatively small proportion of malaria
treatments obtained from retail sector providers (less than 6% of
treatments in one study in 3 rural Tanzanian districts) [9]. A total
of 1080 samples were collected. At the time of collection 32 of
these products had an expiry date that had already passed and
another 51 were set to expire within 6 months of purchase. Data
collectors recorded the district, ward and shop where each sample
was collected and sent the samples with this information onto the
central administrative office of the Ifakara Health Research and
Development Centre in Dar-es-Salaam.
The identifying information from each sample was recorded onto
an electronic data base, including each product’s commercial and
generic name, company and point of origin, batch and lot number,
and the dates of manufacture and expiration (where available).
Samples were retained in their point-of-purchase packaging, sealed
in individual plastic bags and stored in cardboard cartons at room
temperature until shipping and content analysis. The data base and
collected samples were then shipped to the London School of
Hygiene and Tropical Medicine for analyses.
Random tablet selection
To estimate the proportion of substandard products available
for a given drug with 10% precision, 95% confidence and
estimated proportion substandard=0.5, we estimated a sample
size of 95 for each generic class of antimalarial drug. To arrive at
stable estimates of the quality of each generic class collected from
the range of outlet types visited, we chose a stratified random
sample of products for laboratory analysis. The numbers of
antimalarial treatment formulations collected, eligible and selected
for content analyses are identified in Tables 1 and 2. Products with
no expiry date recorded (n=32) or that had reached their expiry
date prior to analysis (n=166) were excluded. We analysed a total
of 301 of 882 eligible antimalarial tablet products. Of 550 eligible
antifolate antimalarial products a sample of 100 was chosen. This
included all samples obtained from general retailers and
pharmacies (a total of 29). The remaining 71 were chosen
randomly from the 521 purchased from drug stores. A total of 58
sulfadoxine/pyrimethamine and 42 sulfamethoxypyrazine/pyri-
methamine products were selected. Out of a total of 223 eligible
amodiaquine products we also chose a sample of 100. This
included all samples collected from pharmacies (total of 7), with
the remaining 93 selected from general retailers and drugs stores in
equal numbers. All eligible quinine and artemisinin derivative
containing tables were analysed, giving a total of 63 quinine and
51 artemisinin derivative -containing monotherapy products
respectively. Samples of other antimalarials collected (6 chloro-
quine, 3 halofantrine and 1 co-packaged mefloquine-artesunate)
were not analysed because the sample size was so small. No co-
formulated artemisinin-containing combination therapy products
were found during data collection.
Tablet packaging and appearance was assessed, coded, and
recorded for each selected product prior to dissolution and content
analyses. However, as packaging was not analysed in detail and
compared with genuine samples we were unable to distinguish
between genuine and counterfeit products. Codes included
whether the tablets were sold in blister packages or loose and
whether tablets were coated or uncoated. Each selected sample
was analysed for quantity of active ingredient using in vitro
dissolution testing protocols following the detailed monograms
Table 1. Antimalarial drug samples collected and eligible for
analyses.
Collected
Expired
before
analyses
No expiry
data
Eligible for
analyses
Amodiaquine 274 36 14 224
Antifol antimalarials 668 107 11 550
Quinine 77 7 7 63
Artemisinin derivatives 51 13 0 38
Chloroquine 6 2 0 4
Halofantrine 3 1 0 2
Mefloquine+Artesunate 1 0 0 1
Total 1080 166 32 882
doi:10.1371/journal.pone.0003403.t001
Table 2. Antimalarial drug samples eligible and selected for analyses, by content and source, 2005.
Antifol antimalarials Amodiaquine Quinine Artemisinin Total
Eligible for analyses
Part I pharmacy 14 7 2 4 27
Part II drug store 15 139 60 34 248
General shop 521 78 1 0 600
Total 550 224 63 38 875
Sample selected for analyses
Part I pharmacy 14 7 2 4 27
Part II drug store 15 46 60 34 155
General shop 71 47 1 0 119
Total analysed 100 100 63 38 301
doi:10.1371/journal.pone.0003403.t002
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the amount of active ingredient using high performance liquid
chromatographic (HPLC) analyses [14]. The test for content
assesses the amount of active ingredient measured in a
formulation, expressed as a percentage of the label claim; the test
for dissolution determines the amount of active ingredient that is
released and available for absorption [4]. Poor manufacturing
practices, poor storage of a product as well as the use of incorrect
excipients will lead to poor dissolution profiles and thus result in
compromised bioavailability. Dissolution testing for pharmaceuti-
cal products in tablet and capsule form is required by the US Food
and Drug Administration (FDA) and increasingly used outside the
USA to report on the quality of drugs.
Dissolution Analyses
Tablet dissolution was performed in the Pharma Test PT 017
dissolution apparatus (Pharma Test Apparatebau, Hainburg,
Germany) using 6 tablets of each product. Dissolution of all
antifolate antimalarial products was carried out using 1 litre of
0.01 M pH 6.8 phosphate buffer solution (sodium hydroxide and
potassium dihydrogen orthophosphate, Fisher Scientific) and heated
to a temperature of 37uC, with a rotor speed of 75 rpm. Dissolution
was carried out for 40 minutes and 500 ml samples were taken at ten
minute intervals during this time. Of this 500 mls a m p l e2 0 0mlw a s
transferred into a HPLC reaction vial and diluted 1:1 with 200 ml
0.05 M pH 6.8 phosphate buffer solution and transferred into the
HPLC machine for analysis. Dissolution of amodiaquine was
performed in 900 mls of purified water and heated to a temperature
of 37uC with a rotor speed of 50 rpm for 30 minutes. At ten minute
intervals, 500 ml samples were taken and from each of these 200 ml
was transferred for HPLC analysis after a 1:1 dilution with purified
water.Quinine tabletsweresubjectedto dissolutionin900 mlsof0.1
Molar HCl and heated to a temperature of 37uC, with a rotor speed
of 100 rpm. Dissolution was carried out for 1 hour with 500 ml
samples taken at ten minute intervals during this time. From each
500 mls a m p l e2 0 0ml was transferred into a HPLC reaction vial and
diluted 1:1 with 200 ml 0.5 MHCl and subsequentlytransferredinto
the HPLC machine for analysis.
Quantity of active ingredient
Drug quality was assessed by comparing the amount of active
ingredient in the eluents of each dissolution sample against a
known concentration of the standard for quinine, amodiaquine,
sulfadoxine and pyrimethamine after HPLC analysis (see chro-
matogram in Figure 2, below for the separation for each
compound). Information about the source, packaging or appear-
ance of each product was not known by the investigators prior to
analyses of the tablets for quality.
After the dissolution and HPLC analyses the samples were
classified as good quality or substandard based on the amount of
active ingredient detected listed in Table 3, below. In the absence
of a published dissolution monograph for sulfamethoxypyrazine,
co-formulations containing this compound were assessed for
pyrimethamine content alone. Similarly in the absence of an
Figure 2. HPLC chromatogram showing the separation of mixture of standards of amodiaquine (AQ), quinine (QU), sulphadoxine
(SUL) and pyrimethamine (PYR) all at 10 mg/ml; dihydroartemisinin (DHA), artesunate (AS) and artemether (AM) at 2 mg/ml.
doi:10.1371/journal.pone.0003403.g002
Table 3. Classification for content analysis by HPLC for
antimalarial drugs.
Good quality
Sulfadoxine .0.3 mg/ml at 30 minutes
Pyrimethamine .0.015 mg/ml at 30 minutes
Amodiaquine .0.167 mg/ml at 30 minutes
Quinine .0.2025 mg/ml at 45 minutes
Artemisinin .95% of expected concentration
doi:10.1371/journal.pone.0003403.t003
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derivatives the tablets were crushed, dissolved in methanol and
an aliquot of the resulting solution was then analysed. The amount
of active ingredient detected was determined from a calibration
curve plotted using reference standards of each of the artemisinin
derivatives (0–10 mgs/ml).
Data analyses
All data from the initial sample collection data base, packaging
and appearance codesand dissolutionand chemical content analyses
were transferred into STATA version 8 for analysis. Laboratory
findings for eachgenericclass of drug obtained from eachoutlet type
were weighted according to the inverse of the probability of selection
inherent in the sampling strategy. All estimates and significance tests
were corrected for clustering within each shop where products were
purchased using the SVY commands. All statistical tests were
evaluated at the p,=0.05 level of precision.
Results
All of the samples had some active ingredient detected.
However, sub-standard products were identified in all generic
classes except the artemisinin derivatives (Table 4-note that the
calculation of percentages reflects adjustments for different
sampling weights across outlet type). Among the antifolate
antimalarial tablet products 7 out of 58 (8.6%) sulfadoxine/
pyrimethamine tablets did not meet the tolerance limits set by
USP for sulfadoxine analysis and one (0.3%) did not meet the
tolerance limits set by USP for pyrimethamine analysis. No tablets
failed to meet the tolerance limits set by USP for both sulfadoxine
and pyrimethamine content analysis. The sulfamethoxypyrazine/
pyrimethamine tablets were analysed for pyrimethamine content
only. Of these, 9 out of 42 (19.8%) tablets did not meet the
tolerance limits set by USP for pyrimethamine and this should be
considered conservative since only one of two active ingredients
was evaluated. Six of 100 amodiaquine products (7.5%) tested
borderline, low or very low. In total 15 out of 63 quinine products
(23.8%) did not to meet the tolerance limits set by USP for content
analysis, scoring within the borderline, low or very low ranges. All
of the 38 formulations of artemisinin derivatives tested were found
to contain the expected amount of each active ingredient.
The proportion of substandard drugs was highest for quinine
tablets (23.8%, 95% CI: 14.8, 35.9), followed by antifolate
antimalarial tablets (13.4%, 95% CI: 7.7, 22.4) and amodiaquine
tablets (7.5%, 95% CI: 3.3, 15.9). The large confidence limits
around these estimates reflect the complex sampling strategy and
would probably have been smaller if resources had been available
to analyse a larger proportion of the samples collected. Details of
the chemical content analysis appear in Table 4 below, along with
data on the factors associated with poor quality.
There was no statistical association between quality of drug and
the type of outlet where it was purchased. Quinine tablets were
Table 4. Numbers and adjusted percentage of samples not meeting the USP tolerance limits for quality test by active ingredient
and potential risk factors.
ANTIFOL‘ SP SMP‘ AQ QN ART Total
N 100 58 42 100 63 38 301
Total failure 17 (13.4) 8 (8.9) 9 (19.8) 6 (7.5) 15 (23.8) 0 (2) 38 (12.2)
Outlet Type:
General Store 1 (6.7) 0 (2) 1 (33.3) 1 (2.1) 1 (100) 0 (2) 3 (5.3)
Part II Drug Store 10 (14.8) 4 (10.5) 6 (18.2) 5 (10.9) 13 (21.7) 0 (2) 28 (13.5)
Part I Pharmacy 6 (42.9) 4 (50.0) 2 (33.3) 0 (2) 1 (50) 0 (2) 7 (25.9)
P value 0.15 0.07 0.56 0.21 0.13 n/a 0.12
Packaging:
Blister 16 (14.8) 7 (10.3) 9 (20.3) 1 (2.0) 3 (13.6) 0 (2) 20 (11.6)
Loose tablets 1 (1.5) 1 (1.7) 0 (2) 5 (19.2) 12 (29.3) 0 (2) 18 (14.9)
P value 0.007* 0.07 0.62 0.01* 0.17 n/a 0.51
Appearance:
Coated tablet none None None none 4 (36.4) 0 (2) 4 (36.4)
Uncoated 17 (13.4) 8 (8.9) 9 (19.8) 6 (7.5) 11 (21.2) 0 (2) 34 (11.9)
P value undefined undefined undefined undefined 0.29 n/a 0.02*
Stated country of origin:
Tanzania 4 (11.9) 3 (11.7) 1 (12.5) 5 (13.2) 7 (18.4) 0 (2) 16 (12.6)
Imported 13 (14.1) 5 (7.3) 8 (21.8) 1 (1.5) 8 (32.0) 0 (2) 22 (12.0)
P value 0.79 0.59 0.58 0.017* 0.22 n/a 0.90
Size of trading centre:
Major trading centre 15 (15.9) 8 (21.9) 7 (10.2) 4 (7.0) 13 (27.1) 0 (2) 32 (12.1)
Non-major trading centre 1 (0.9) 1 (6.0) 0 (2) 1 (8.8) 2 (15.4) 0 (2) 4 (3.9)
P value 0.0002* 0.21 0.22 0.83 0.39 n/a 0.03*
‘ANTIFOL antimalarials include SP and SMP. SMP samples were tested against only the pyrimethamine standard and should therefore be considered conservative
estimates of failure rates.
*Statistically significant at the 0.05 level based on the corrected chi square test.
doi:10.1371/journal.pone.0003403.t004
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not significantly so. It is possible that this reflected the high
proportion of quinine samples which were obtained loose rather
than in blister packs, though again; though the proportion of
failures Overall, in bivariate analyses tablets purchased from major
trading centres and coated tablets were more likely to be
substandard. Since quinine tablets were the only products that
were coated, the latter finding may be confounded by the relatively
high failure rate of quinine products relative to other antimalarial
drug classes. Amodiaquine products sold loose rather than in
blister packs were significantly more likely to be sub-standard, but
the opposite was found for antifolate tablets, where those in blisters
were significantly more likely to fail. Antifolate antimalarial
products obtained at major trading centers were substantially
more likely to fail quality testing than those purchased in non-
major trading centres. This could reflect a concentration of
substandard drug in the locations where retail activity is most
extensive. While the proportion of imported and locally produced
products that failed content analysis was nearly identical, there was
a statistically significant association between a stated Tanzanian
origin, and poor quality for amodiaquine products. We developed
logistic regression models to assess for the multiple predictors of
poor quality drug (generic drug class, type of outlet, country of
origin, tablet packaging and appearance and size of trading
centre), as well as potential interaction terms. None of these factors
were found to be independent predictors of substandard medicines
(data not shown).
Discussion
A high prevalence of sub-standard antimalarials in the African
retail sector is of great importance in view of the frequency of their
use for fever/malaria treatment. Moreover, discussions are
currently underway at an international level on strategies to
increase access to effective antimalarials through the retail sector
through the application of a global subsidy for artemisinin-based
combination therapy (ACT). Tanzania has already piloted such a
subsidy through Part II drug stores in 2 rural districts [15], and
now plans to scale this up nationwide [16].The importance of the
retail sector as a delivery channel for antimalarials is therefore
likely to increase, further emphasizing the need for regular
nationwide monitoring of antimalarial quality.
This study represents the first nationwide survey of antimalarial
tablet quality in the African retail sector. Our results showed that
poor quality antimalarials were common–12.2% of all samples
were substandard, and the figure was as high as 23.8% for quinine,
which at the time of the study was the third line antimalarial and
first choice for severe disease. The frequency of poor quality
formulations was also unacceptably high for antifolate antimalarial
drugs (13.4%) which were the first line drug at the time. Moreover,
these figures are likely to be an underestimate of true percentages
of poor quality as firstly it was not possible to test the dissolution
profile for sulphamethoxypyrazine component of the SMPs, and
secondly all drugs which had expired by the time of analysis, or
had no expiry date recorded were excluded from analysis. No clear
predictors of poor quality were identified in this study; substandard
antimalarials were obtained from all parts of the country, in major
and non-major trading centres, from all types of retail outlet, from
both local and international manufacturers, and were identified
among both blister packed and loose tablet samples.
Collecting systematic samples of products available in a diverse
and far-flung retail market can be a daunting task. In this study, we
were able to collect drug samples from major and non-major trading
centres in a probability-based selection of districts across mainland
Tanzania by joining forces with a separate study on bednets. The
method for selection of trading centres within districts was designed
to ensure that the most important trading centres were included
alongwitha sampleofthe smaller commercialcentres.However,the
sample is not strictly representative in terms of all market centres,
and in particular may have under-represented those of medium size.
Moreover, we collected one treatment course of all antimalarial
tablets that were available on the day of survey, which does not
necessarily represent the true range of products that would be
obtained and used by consumers. Preferences for particular drug
classes, brand names, formulation, packaging and price would all be
expected to affect consumer choice. These factors could not be
reflected in our sampling strategy. In addition, because they knew
they were participating in a research study, shop attendants may
have concealed certain unregistered, expired or short-dated
pharmaceuticals and products of dubious provenance from data
collectors. Even so, our study demonstrates that it is possible to
conduct a systematic nationwide assessment of the quality of
antimalarial products available in the retail sector and offers a
model approach for further research and regulatory work.
We did not assess whether products were counterfeit (i.e.
deliberately and fraudulently mislabelled with respect to identity or
source) and therefore we only comment on the percent that were
found sub-standard. Counterfeit antimalarials have been document-
ed in Africa, for example in Cameroon tablets sold as quinine were
found to contain chloroquine instead [17] and counterfeit
artemisinin derivatives in Democratic Republic of Congo [Atemn-
keng]. The samples were collected from outlets serving the rural
population directly. This is important because transport and storage
conditions can be a cause of sub-standard medicines [4], a factor
which will not be captured when only wholesalers or the main urban
pharmacies are sampled. This approach provides a picture of the
quality of antimalarials available at the grass-roots; however, it does
not allow us to identify the cause of the problem and in particular
whether it arose pre or post-factory gate. Little evidence is currently
available on antimalarial stability in tropical climates [4].
The frequency of sub-standard antimalarials has varied across
studies in Tanzania, but can be difficult to compare across the
divergent sampling approaches used. A contemporaneous study
from Kilombero and Ulanga Districts of antimalarials obtained
from 43 shops and 9 facilities found a higher frequency of sub-
standard tablets than our nationwide study, but a similar pattern
across generic type: 9% of 35 amodiaquine samples failed on
content, compared with 26% of 61 SP samples, and 39% of 33
quinine samples [18]. Two earlier small scale studies in Dar es
Salaam also found high frequencies of substandard drugs. Minzi et
al’s study of 8 wholesalers found 13% of 15 amodiaquine samples
failed the dissolution test, but all passed the assay for content, and
11% and 44% of 18 SP samples failed the content and dissolution
tests respectively [19]. Risha et al also obtained samples from Dar
es Salaam wholesalers, and from the Medical Stores Department
in 2000 [20]. Of 4 SP products tested they found that 2 failed the
dissolution test. High rates of failure have also been documented
elsewhere in Africa. In a recent review Amin and Kokwaro
documented 48 studies of content and 30 of dissolution (for
multicountry studies each country and each drug class was
considered a separate study). In 31 of the 48 content studies more
than 80% of samples had appropriate content, although the
performance of quinine was noticeably poorer than for other
antimalarials. In only 14 of the 30 dissolution studies did more
than 80% of samples perform satisfactorily [4].
It was encouraging to note that no artemisinin products failed
our quality testing despite a wide range of countries of
manufacture including Belgium, France, China, India, Tanzania,
Retail Antimalarial Quality
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unwarranted. Atemnkeng et al found both sub-standard and
counterfeit artemisinin-based products in Kenya and DR Congo
[21], and Bate et al found sub-standard products in Ghana,
Kenya, Nigeria, Tanzania and Uganda [22]. Moreover, there is
strong evidence of high prevalence of counterfeit artemisinin
products circulating in South East Asia, usually containing no
active ingredient. Surveys in Burma (Myanmar), the Thai/
Burmese border, the Lao People’s Democratic Republic, Cambo-
dia and Vietnam indicate that 33–53% of artesunate purchased
was counterfeit [8]. Artemisinin products are already common in
the African commercial sector, particularly in wealthier urban
areas. For example, at the time of this study, 19 different
artemisinin products were identified from pharmacies in Dar es
Salaam [23]. The number is likely to have increased since then,
partly in response to the switch to artemisinin-based combination
therapy as the first line for treatment of uncomplicated malaria as
well as an increasing number of artemisinin-containing products
registered with the Tanzania Food and Drugs Authority.
Conclusion
Antimalarial drugs purchased through the retail sector are one
of the key tools used by poor African households to control
malaria, and lead to significant household costs. It is therefore
essential that the quality and safety of these medicines is assured.
This study has demonstrated that a high proportion of retail sector
antimalarials in rural Tanzania are of poor quality. However, drug
quality is rarely assessed on a large scale, in part due to lack of
dedicated laboratory facilities which are expensive to build, equip,
set up and maintain in resource poor countries. Similar systematic
nation-wide studies of drug quality are warranted on a regular
basis throughout the region ensure that the negative consequences
of sub-standard drugs are avoided, and that any influx of
counterfeit medicines is identified early and addresses.
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